Ozmosi | Carbimazole Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Carbimazole

Alternative Names: carbimazole
Clinical Status: Inactive
Latest Update: 2024-05-14
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Iodine Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Algeria | Australia | Austria | Bangladesh | Cyprus | Denmark | Dominican Republic | Egypt | Finland | France | Greece | Hong Kong | Iceland | India | Indonesia | Ireland | Jordan | Korea | Malaysia | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Philippines | Saudi Arabia | Singapore | South Africa | Spain | Sri Lanka | Switzerland | Taiwan | Ukraine | United Arab Emirates | United Kingdom | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Newcastle-upon-Tyne Hospitals NHS Trust
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Graves Disease

Phase 3: Thyrotoxicosis|Hyperthyroidism|Graves Disease

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT03064542

 TRIBUTE

N/A

Completed

Hyperthyroidism

2023-05-19

2023-05-26

Primary Endpoints|Treatments

NCT05385029

 COVID-19

N/A

Completed

Severe Acute Respiratory Syndrome|Hypothyroidism|Hyperthyroidism|COVID-19

2021-09-30

2022-05-27

Primary Endpoints|Treatments

NCT00430547

 NCT00430547

N/A

Completed

Graves Disease|Graves Ophthalmopathy

None

2019-03-21

Treatments

NCT03303053

 ChoPS

P3

Unknown status

Graves Disease|Hyperthyroidism

2018-03-01

2019-10-03

Primary Endpoints|Treatments|Trial Status

NCT01436994

 NUTH 2759

P3

Completed

Thyrotoxicosis

2014-12-01

2019-03-19

Treatments

ACTRN12615000362594

 ACTRN12615000362594

P4

Terminated

Graves Disease

2016-09-06

2026-02-15

Treatments

Recent News Events

Date

Type

Title

05/14/2024

PubMed

 Eltroxin and Hesperidin mitigate testicular and renal damage in hypothyroid rats: amelioration of oxidative stress through PPARĪ³ and Nrf2/HO-1 signaling pathway.

05/02/2024

PubMed

 Cardiac evaluation in amiodarone-induced thyroid dysfunction with suspected cardiac ischemia?: a case report and review of the literature.

03/15/2024

PubMed

 Lemierre's Syndrome Caused by Streptococcus pneumoniae in a Patient with Carbimazole-Induced Severe Neutropenia.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions